Background A wide spread of chloroquine resistance prompted its discontinued use for
treatment of uncomplicated malaria in several African countries. However, disappearances …

The rapid and aggressive spread of artemisinin-resistant Plasmodium falciparum carrying
the C580Y mutation in the kelch13 gene is a growing threat to malaria elimination in …

Background Usage of chloroquine was discontinued from the treatment of Plasmodium
falciparum infection in almost all endemic regions because of global spread of resistant …

Background The analysis of single nucleotide polymorphism (SNPs) in drug-resistance
associated genes is a commonly used strategy for the surveillance of anti-malarial drug …

Background Mizoram, a northeastern state in India, shares international borders with
Myanmar and Bangladesh and is considered to be one of the key routes through which drug …

Abstract Background The C580Y mutation in the Plasmodium falciparum kelch13 gene is
the most commonly observed variant in artemisinin-resistant isolates in the Greater Mekong …

In Uganda, artemether-lumefantrine was introduced as an artemisinin-based combination
therapy (ACT) for malaria in 2006. We have previously reported a moderate decrease in ex …

Meplazumab is an anti-CD147 humanized IgG2 antibody. The purpose of this study was to
characterize the nonclinical safety, tolerance and efficacy evaluation of meplazumab treating …

Plasmodium falciparum, the cause of the most lethal malaria in humans, which still remains
a threat to global health, with children and pregnant women being the most affected. This …

The spread of drug resistance of Plasmodium falciparum and Plasmodium vivax parasites is
a challenge towards malaria elimination. P. falciparum has shown an early and severe drug …